Literature DB >> 12698670

Neurohumoral activation and ventricular arrhythmias in patients with decompensated congestive heart failure: role of endothelin.

Doron Aronson1, Andrew J Burger.   

Abstract

Patients with congestive heart failure (CHF) have a high incidence of ventricular arrhythmias and sudden arrhythmic death. CHF entails profound and complex abnormalities in humoral responses that are thought to promote arrhythmic events. However, it is unknown which of the many endogenous mediators that accumulate as part of neurohormonal activation is important in arrhythmogenesis in the setting of CHF. The study included 83 patients admitted to the hospital for treatment of decompensated CHF. Neurohormonal and cytokine activation was assessed by measuring plasma renin activity, aldosterone, norepinephrine, endothelin-1, tumor necrosis factor-alpha, and interleukin-6 levels. Atrial and ventricular arrhythmic events were assessed by 24-hour Holter monitoring. In a univariate analysis, a highly significant, positive relationship was found between plasma endothelin-1 levels and the average hourly total premature ventricular beats (P = 0.003), the frequency of ventricular pairs (P = 0.0003), and the frequency of ventricular tachycardia episodes (P = 0.001). After inclusion of clinical variables, drug therapies, neurohormones, and cytokine levels in a multivariate analysis, the positive relationship between plasma endothelin-1 level and the average hourly total premature ventricular beats (P = 0.008), the frequency of ventricular pairs (P = 0.007), and ventricular tachycardia episodes (P = 0.009) remained independent. No association between other neurohormones or cytokines and arrhythmic events was demonstrated. The results of the present study suggest that increased endothelin-1 concentrations may be involved in promoting the occurrence of ventricular ectopy in patients with decompensated CHF. Proarrhythmic effects may account, in part, for the poor outcome associated with increased endothelin-1 levels in patients with decompensated CHF.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12698670     DOI: 10.1046/j.1460-9592.2003.00120.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  6 in total

Review 1.  Pathophysiology and clinical evaluation of acute heart failure.

Authors:  Robert J Mentz; Christopher M O'Connor
Journal:  Nat Rev Cardiol       Date:  2015-09-15       Impact factor: 32.419

Review 2.  The disconnect between phase II and phase III trials of drugs for heart failure.

Authors:  Muthiah Vaduganathan; Stephen J Greene; Andrew P Ambrosy; Mihai Gheorghiade; Javed Butler
Journal:  Nat Rev Cardiol       Date:  2013-01-08       Impact factor: 32.419

Review 3.  The cardiovascular physiology and pharmacology of endothelin-1.

Authors:  Eric Thorin; Martine Clozel
Journal:  Adv Pharmacol       Date:  2010

Review 4.  Acute heart failure: patient characteristics and pathophysiology.

Authors:  Catherine N Marti; Vasiliki V Georgiopoulou; Andreas P Kalogeropoulos
Journal:  Curr Heart Fail Rep       Date:  2013-12

5.  Correlation of Ventricular Arrhythmogenesis with Neuronal Remodeling of Cardiac Postganglionic Parasympathetic Neurons in the Late Stage of Heart Failure after Myocardial Infarction.

Authors:  Dongze Zhang; Huiyin Tu; Chaojun Wang; Liang Cao; Robert L Muelleman; Michael C Wadman; Yu-Long Li
Journal:  Front Neurosci       Date:  2017-05-08       Impact factor: 4.677

Review 6.  Classic and Novel Biomarkers as Potential Predictors of Ventricular Arrhythmias and Sudden Cardiac Death.

Authors:  Zornitsa Shomanova; Bernhard Ohnewein; Christiane Schernthaner; Killian Höfer; Christian A Pogoda; Gerrit Frommeyer; Bernhard Wernly; Mathias C Brandt; Anna-Maria Dieplinger; Holger Reinecke; Uta C Hoppe; Bernhard Strohmer; Rudin Pistulli; Lukas J Motloch
Journal:  J Clin Med       Date:  2020-02-20       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.